Hugel is expanding US Letybo with a direct sales force, field medical affairs, and a K-TOX campaign. Over 9,000 US practices have adopted the FDA-approved toxin.
Hugel is scaling US sales of Letybo, its FDA-approved neurotoxin for glabellar lines, by adding a direct sales force, field medical affairs, and a consumer K-TOX campaign. More than 9,000 US practices have adopted Letybo since its March 2025 launch through the BENEV partnership.
On July 21, 2026, South Korea based Hugel Aesthetics announced a broad expansion of its US commercial, medical, and scientific operations behind Letybo (letibotulinumtoxinA-wlbg), its botulinum toxin type A neuromodulator. Letybo is FDA-approved for the temporary improvement of moderate to severe glabellar lines, the vertical frown lines between the eyebrows. It is not approved for other cosmetic or therapeutic uses.
The move adds a dedicated direct sales force and a field based medical affairs team to a US business that, until now, has run through a distribution partnership with BENEV Company. Hugel is pairing that commercial buildout with a consumer facing campaign it calls K-TOX. The company says more than 9,000 US practices have adopted Letybo since it launched in March 2025.
Hugel Aesthetics said it is standing up a dedicated US direct sales organization and a field based medical affairs team for Letybo, alongside investments in medical education, congress support, and clinical research. The company is moving to a hybrid commercial model: BENEV Company will continue to service specific accounts, while Hugel's new direct sales team focuses on select strategic accounts through 2026.
The consumer element is K-TOX, a marketing campaign that leans on Letybo's South Korean heritage. Hugel says Letybo has been the best selling neurotoxin in South Korea for 10 years, in a market where more than 15 neuromodulator products compete. The company reports the toxin has been used in more than 44 million treatments across 70 plus countries. Letybo received FDA approval in February 2024 and launched in the US in March 2025 through the BENEV partnership.
The US neurotoxin market is crowded. Letybo competes against long established brands and newer entrants for the same glabellar lines indication. A direct sales force and dedicated medical affairs team signal that Hugel intends to build lasting provider relationships rather than rely solely on a distributor, which can mean more direct clinical education and account support for practices.
For consumers, the K-TOX campaign is a branding and awareness play, not a change to what Letybo is approved to treat. Every FDA-approved botulinum toxin for glabellar lines, including Letybo, addresses the same narrow cosmetic indication. Marketing that emphasizes national origin or market rank does not expand a product's approved uses or establish that one toxin is clinically superior to another. Head to head superiority claims between neurotoxins are generally not supported by direct comparative trial data.
Watch whether wider distribution and consumer marketing change how Letybo is priced and offered at the practice level, and whether Hugel pursues additional indications beyond glabellar lines in the US. Any expansion of approved uses would require separate FDA review; until then, use outside glabellar lines would be off-label.
Patients considering any neurotoxin should focus on the injector's training and the product's approved indication rather than a marketing campaign or country of origin. Letybo is a prescription product administered by a licensed clinician, and results, longevity, and suitability vary by individual. This report is informational and does not recommend starting or choosing any specific treatment.